Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est

Rivet, V.; Quantin, Xavier; Faillie, Jean‐Luc; Lesage, C.; Meunier, L.; Faure, Stéphanie; Hillaire‐Buys, Dominique; Lesouder, C.; Fabre, S.; Assenat, Éric; Rullier, P.; Guilpain, Philippe; Maria, A.

doi:10.1016/j.revmed.2021.01.002

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This meeting called ‘RCP ToxImmun’ had been set up in December 2018 and allows the validation of diagnoses, standardization of management, and discussion of possible retreatment with ICI. 33 …”

Section: Discussionmentioning

confidence: 99%

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study

Colard-Thomas,

Manceron,

Duflos

et al. 2023

ESMO Open

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study

Colard-Thomas,

Manceron,

Duflos

et al. 2023

ESMO Open

Self Cite

View full text Add to dashboard Cite

Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes

Guitton,

Lambotte,

Chiche

2024

La Revue de Médecine Interne

View full text Add to dashboard Cite

Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board

Varnier,

Fontaine-Delaruelle,

Freymond

et al. 2024

JCO Oncol Pract

View full text Add to dashboard Cite

PURPOSE The management of immune-related adverse events (irAEs) requires multidisciplinary boards to handle complex cases. This study aimed to examine the evolving practices of the IMMUCARE board and to evaluate its impact on clinical practices. MATERIALS AND METHODS The IMMUCARE board gathers oncologists and organ specialists from the Cancerology Institute of the Lyon University Hospital since 2018. We conducted a retrospective analysis of its activity (participants' specialty, referred cases, and recommendations) from 2018 to 2021, coupled with a survey among the physicians who participated. RESULTS Across 68 board meetings, 245 cases from 195 patients were discussed. Each board had a median of six participants (IQR, 5-8). Participation rates varied across specialties and also over time (participation of nephrologists and rheumatologists significantly increased over time, whereas it decreased for endocrinologists). Most of the referred patients (89%) were treated at our center. Only 4% of referrals concerned eligibility for immune checkpoint inhibitor (ICI), whereas the majority pertained to irAEs. The board recommended ICI interruption for 56% and steroids for 41% of them. Immunosuppressants were recommended in 17% of cases, with a notable increase over time. ICI reintroduction was debated in 50% of cases, and the board identified a definitive contraindication in 26% of them. The survey of 49 of 98 physicians showed that the board significantly affected immunosuppressant introduction and ICI rechallenge decisions. The board's educational and collaborative benefits were highlighted, but time constraints posed challenges. CONCLUSION Our 4-year analysis of irAE management practices reveals changing patterns in the distribution of cases presented and in specialists' involvement. Dedicated multidisciplinary boards remain essential, particularly for intricate cases. Expanding access to these boards is crucial to ensure comprehensive care for all patients.

show abstract

Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est

Cited by 3 publications

References 38 publications

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study

Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes

Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board

Contact Info

Product

Resources

About